2025-05-02 08:59:31
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Gland Pharma Ltd Q3FY21 net profit at Rs. 204.10 crore
Posted On : 2021-01-22 17:22:40( TIMEZONE : IST )
Gland Pharma Ltd has reported financial results for the period ended December 31, 2020.
Financial Results (Q3 FY20-21) - QoQ Comparison
The company has reported total income of Rs.894.54 crores during the period ended December 31, 2020 as compared to Rs.851.85 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.204.10 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.218.85 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.12.82 for the period ended December 31, 2020 as compared to Rs.14.12 for the period ended September 30, 2020.
| Financials | Q3 FY20-21 | Q2 FY20-21 | % Change |
| Total Income | ₹ 894.54 crs | ₹ 851.85 crs |  5.01% |
| Net Profit | ₹ 204.10 crs | ₹ 218.85 crs |  -6.74% |
| EPS | ₹ 12.82 | ₹ 14.12 | -9.21% |
Financial Results (Q3 FY20-21) - YoY Comparison
The company has reported total income of Rs.894.54 crores during the period ended December 31, 2020 as compared to Rs.671.22 crores during the period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.204.10 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.154.09 crores for the period ended December 31, 2019.
The company has reported EPS of Rs.12.82 for the period ended December 31, 2020 as compared to Rs.9.95 for the period ended December 31, 2019.
| Financials | Q3 FY20-21 | Q3 FY19-20 | % Change |
| Total Income | ₹ 894.54 crs | ₹ 671.22 crs | 33.27% |
| Net Profit | ₹ 204.10 crs | ₹ 154.09 crs | 32.46% |
| EPS | ₹ 12.82 | ₹ 9.95 | 28.84% |
Financial Results (9 Months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.2662.69 crores during the 9 months period ended December 31, 2020 as compared to Rs.2090.96 crores during the 9 months period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.736.55 crores for the 9 months period ended December 31, 2020 as against net profit / (loss) of Rs.578.06 crores for the 9 months period ended December 31, 2019.
The company has reported EPS of Rs.47.10 for the 9 months period ended December 31, 2020 as compared to Rs.37.31 for the 9 months period ended December 31, 2019.
| Financials | 9 Months ended FY20-21 | 9 Months ended FY19-20 | % Change |
| Total Income | ₹ 2662.69 crs | ₹ 2090.96 crs | 27.34% |
| Net Profit | ₹ 736.55 crs | ₹ 578.06 crs | 27.42% |
| EPS | ₹ 47.10 | ₹37.31 | 26.24% |
Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said "Our growth momentum has continued in the third quarter and we reported Revenue growth of 33% and Net Profit growth of 32% over the corresponding quarter of the previous year. The business growth drivers were new product launches, geographic expansion of business and volume growth in existing portfolio, which is in line with our strategy. During the quarter, 12 ANDAs were filed from our sites and 6 ANDA approvals were obtained. We have also filed 1 DMF during the same period. Our success is predicated by our ability to deliver products without compromising on the quality, safety, and customer satisfaction. We are committed to our objective of building a sustainable business model to achieve long term profitable growth."
